BioLingus is a Swiss biotech company spearheading the development of oral (sublingual)
delivery of peptides and proteins for chronic diseases and immuno-therapy via our innovative formulation technology.
Our company focuses on the development of products for
treatment of metabolic diseases and various immuno-therapies.
- WuXi STA and BioLingus sign exclusive technology and marketing collaboration for sublingual delivery,Feb 2019
- Biolingus receives Award for “Best European Biotech Company 2018”
- BioLingus proud winner of the 2018 Red Herring Top100 Award
- BioLingus in list of"Top 20 Most Influential Companies"from CEO Insight
Corporate Partnerships
To further exploit the potential of the BioLingus Technology, we are interested in exploring partnerships with other pharmaceutical companies. Aside from pharmaceutical companies, we are also interested in working with animal health companies" (with adjusted formulations) and food companies working on innovative food supplements.
Together we unlock the potential of the BioLingus Technology, and thus transform current standard practices in the administration of peptides and proteins.
